ArticleJACC. Asia2026
Temporal Trends and Outcomes in Low-Risk Patients Undergoing TAVI: Insights From the LAPLACE-TAVI Registry.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter aortic valve implantation is now indicated in low-risk patients following favorable outcomes in clinical trials and real-world registries.
objectivesThe authors aimed to investigate temporal trends and long-term outcomes in this population.
methodsUsing a multicenter registry database (2010-2025), we stratified 5,691 patients by their Society of Thoracic Surgeons scores: low risk (<4%, n = 1,580 of 5,691 [27.8%]), intermediate risk (4% to 8%, n = 2,388 of 5,691 [42.0%]), and high risk (>8%, n = 1,723 of 5,691 [30.3%]). Low-risk patients were further classified according to clinical trial eligibility. The primary outcomes were crude 30-day and Kaplan-Meier-estimated 4-year all-cause mortalities.
resultsThe annual procedure volume among low-risk patients did not show a sustained increase and declined after peaking in 2022. Low-risk patients were younger, predominantly male, had a higher body mass index (BMI), fewer comorbidities, and fewer procedural complications. They also demonstrated higher rates of elective procedure and transfemoral access. Thirty-day mortality and procedural complication rates remained consistently low among the low-risk cohort; furthermore, 4-year mortality was the lowest among trial-eligible low-risk patients (overall follow-up: 2.2 years). Clinical trial eligibility criteria (frailty [HR: 2.43; 95% CI: 1.43-4.14; P = 0.003] and renal dysfunction [HR: 3.00; 95% CI: 1.46-6.20; P = 0.010]), female sex (HR: 0.62; 95% CI: 0.44-0.89; P = 0.009), BMI (HR: 0.94 per kg/m
conclusionsDespite the overall expansion of transcatheter aortic valve implantation, procedure volume among low-risk patients has not consistently increased. Clinical trial eligibility, female sex, BMI, and albumin levels may refine risk stratification in Society of Thoracic Surgeons-defined low-risk patients. (Outcomes of transcatheter aortic valve implantation in Japanese patients with aortic stenosis: LAPLACE-TAVI registry; UMIN000031133).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.